Global Transdermal Drug Delivery System Market Growth (Status and Outlook) 2023-2029

Global Transdermal Drug Delivery System Market Growth (Status and Outlook) 2023-2029

Product Code:457102

Published Date: Feb 08,2023

Pages: 110

Region: Global

Category: Medical Care

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

LPI (LP Information)' newest research report, the “Transdermal Drug Delivery System Industry Forecast” looks at past sales and reviews total world Transdermal Drug Delivery System sales in 2022, providing a comprehensive analysis by region and market sector of projected Transdermal Drug Delivery System sales for 2023 through 2029. With Transdermal Drug Delivery System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transdermal Drug Delivery System industry.

This Insight Report provides a comprehensive analysis of the global Transdermal Drug Delivery System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transdermal Drug Delivery System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transdermal Drug Delivery System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transdermal Drug Delivery System and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transdermal Drug Delivery System.

The global Transdermal Drug Delivery System market size is projected to grow from US$ 14730 million in 2022 to US$ 36410 million in 2029; it is expected to grow at a CAGR of 13.8% from 2023 to 2029.

Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent. 
In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.

This report presents a comprehensive overview, market shares, and growth opportunities of Transdermal Drug Delivery System market by product type, application, key players and key regions and countries.

Market Segmentation:
Segmentation by type
    Fentanyl
    Nitroglycerin
    Estradiol
    Nicotine
    Other

Segmentation by application
    OTC
    Rx

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
    Hisamitsu
    Mylan
    GSK
    Novartis
    Teve (Actavis)
    Johnson & Johnson
    Lohmann
    Teikoku Seiyaku
    Bayer
    Lingrui
    Sanofi
    Qizheng
    Endo
    Huarun 999
    Haw Par
    Nichiban
    Mentholatum
    Laboratoires Genevrier